London-based healthtech startup Semble has secured a large Series C investment of £30M to help develop its connected healthcare management technology for outpatient providers. The large investment comes at a pivotal moment for Europe’s healthcare industry, which is under major operational pressure due to a lack of integrated technology, surging patient numbers and a stark trend away from public and toward self-paying private healthcare.
The new round was led by European growth investor Revaia, with a new investor in Partech. Existing investors Mercia Ventures and Octopus Ventures also increased their investment. Semble’s total fundraising is now nearly £57m.
An Interoperable Layer for Outpatient Care
Semble is a platform that was purpose-built to combat the deep fragmentation of modern healthcare’s digital infrastructure. Established in 2018 by Christoph Lippuner and Mikael Landau (originally as Heydoc, until a brand repositioning in early 2022), Semble was born out of the need to address the pain points of digital fragmentation across healthcare in general. Healthcare traditionally relied on a collection of individual software services representing separate steps in a patient’s care friction for staff and data transfer.
Source: Semble
Semble is a single, open EHR and practice management system that is completely interoperable. It manages the patient experience end to end, including online scheduling, automated forms and intake, billing, diagnostics, and lab results. To date, there are over 1,200 connectors that allow Semble to interface with pre-existing third-party CRM services, financial systems such as Stripe and Xero, and specialised lab networks.
This system design allows individual practitioners, larger multi-site clinics, or massive corporate health organisations to keep their data closer to one place. The use of the platform as a “one-stop shop” allows the smooth operation of the system, greatly decreasing the amount of repetition involved in admin tasks and helping clinicians to get some of that precious time back to treat patients.
More News: Quobly Closes €115M Series A for Quantum Growth
Fueling European Expansion and AI Orchestration
The £30 million capital injection will be allocated toward pursuing research and development work, especially on developing Semble’s platform as an intelligent artificial intelligence orchestration layer. The platform hopes to cut down the clinical administrative overhead even more by using AI to automate clinical workflows and data synthesis.
Furthermore, the funds will also allow for market adoption by the broader and more complex enterprise-tier health systems and bolster Semble’s presence across the European continent. Although already present in the UK, the company has elected France as the next hotspot for growth, and one year after getting regulatory clearance for France, along with the platform achieving technical readiness, it has been adopted by French outpatient networks at speed.
Over 16,000 healthcare professionals are using the software, which covers 80 medical disciplines in over 1,700 separate healthcare organisations. Customers include a wide number of corporate clients (Nuffield Health, London Doctors Clinic, Welbeck, Midland Health, and others) and healthcare providers (Modality and ProblemShared). Over 10 million patients have been treated by a clinician working within the system.
With private health insurance growth accelerating not only across the UK but also throughout Europe, there is an increasing need for digital tools that are scalable, efficient and easy to use in the field of private medicine. With its new seed funding, Semble is ready to overcome the legacy and dull health record systems, creating a more flexible infrastructure for medicine.
Source link
